Pulmatrix (PULM) Depreciation & Amortization (CF) (2013 - 2024)
Pulmatrix (PULM) posted Depreciation & Amortization (CF) of $47000.0 for Q2 2024, down 20.34% sequentially from $59000.0 in Q1 2024, and up 46.88% YoY from $32000.0 in Q3 2023.
Pulmatrix (PULM) Depreciation & Amortization (CF) (2013 - 2024) Analysis & Trends
Pulmatrix has reported Depreciation & Amortization (CF) for 12 years, with the latest figure at $47000.0 in Q2 2024.
- Quarterly Depreciation & Amortization (CF) rose 46.88% year-over-year to $47000.0 in Q2 2024, while the trailing twelve-month figure through Mar 2025 was $47000.0 (down 70.81% YoY) and the FY2024 annual result came in at $106000.0, down 20.9% from the prior year.
- Depreciation & Amortization (CF) slipped to $47000.0 in Q2 2024 per PULM's latest filing, from $59000.0 in the prior quarter.
- Over five years, Depreciation & Amortization (CF) peaked at $59000.0 in Q1 2024 and troughed at $32000.0 in Q1 2023.
- A 5-year average of $43666.7 and a median of $43500.0 in 2021 frame the typical range for Depreciation & Amortization (CF).
- The sharpest annual moves came in 2020 and 2021: Depreciation & Amortization (CF) soared 146.03% in 2020, then plunged 39.66% in 2021.
- Over 5 years, Depreciation & Amortization (CF) stood at $58000.0 in 2020, then slumped by 39.66% to $35000.0 in 2021, then increased by 11.43% to $39000.0 in 2022, then dropped by 2.56% to $38000.0 in 2023, then grew by 23.68% to $47000.0 in 2024.
- According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $47000.0, $59000.0, and $38000.0 for Q2 2024, Q1 2024, and Q4 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pulmatrix | 5.46 Mn | 5.46 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 47,000.00 |
| Jun 30, 2024 | 47,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Mar 31, 2024 | 59,000.00 |
| Dec 31, 2023 | 38,000.00 |
| Dec 31, 2023 | 38,000.00 |
| Sep 30, 2023 | 32,000.00 |
| Sep 30, 2023 | 32,000.00 |
| Jun 30, 2023 | 32,000.00 |
| Jun 30, 2023 | 32,000.00 |
| Mar 31, 2023 | 32,000.00 |
| Mar 31, 2023 | 32,000.00 |
| Dec 31, 2022 | 39,000.00 |
| Dec 31, 2022 | 39,000.00 |
| Sep 30, 2022 | 41,000.00 |
| Sep 30, 2022 | 41,000.00 |
| Jun 30, 2022 | 47,000.00 |
| Jun 30, 2022 | 47,000.00 |
| Mar 31, 2022 | 35,000.00 |
| Mar 31, 2022 | 35,000.00 |